Engineered fibroblast growth factor variants as receptor antagonists

A growth factor, human fibroblast technology, applied in the field of polypeptide variants, can solve problems such as lack of easy-to-adapt methods

Inactive Publication Date: 2021-07-30
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF29 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The lack of readily adaptable methods for engineering proteolytic stability may partly explain the limited development of proteolytically stable growth factors to date

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Engineered fibroblast growth factor variants as receptor antagonists
  • Engineered fibroblast growth factor variants as receptor antagonists
  • Engineered fibroblast growth factor variants as receptor antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0348] Example 1: High throughput screening method for engineering proteolytically stable growth factors

[0349] Summary

[0350] Growth factors are an important class of regulatory proteins with great potential for development as therapeutic molecules for regenerative medicine and cancer therapy. However, the activity and efficacy of growth factors as therapeutic molecules are greatly limited due to their poor thermostability and proteolytic stability. Although many methods have been developed to engineer growth factors with increased thermostability, there is a lack of attention and method development to develop engineered growth factors with increased proteolytic stability. Proteases such as plasmin, elastase, uPA, cathepsins and MMPs play key roles in extracellular matrix degradation and signal transduction, especially in wound healing and tumor formation. These proteases are also reported to degrade growth factors in general. In this work, a general method for enginee...

Embodiment 2

[0386] Example 2: Engineered Proteolytically Stabilized Fibroblast Growth Factor

[0387] Summary

[0388] FGF1 plays an important role in cell differentiation and induction of angiogenesis during wound healing, tissue regeneration, tumor formation and other angiogenesis-dependent diseases. Therefore, FGF1-based agonists and antagonists may have important applications in cell culture and protein therapy. However, FGF1 has been reported to exhibit sensitivity to degradation when exposed to proteases in culture. Its poor proteolytic stability may hamper their activity and efficacy in cell culture or when developed as therapeutic molecules. In this example, FGF1 peptides were engineered for proteolytic stability using the yeast display-based screening method described in Example 1. A gating strategy for selection of proteolytically stable FGFs was explored and successfully identified characterization candidates.

[0389] introduction

[0390] Fibroblast growth factor (FGF) i...

Embodiment 3

[0429]Example 3: Characterization of Proteolytically Stabilized Fibroblast Growth Factor

[0430] Summary

[0431] Proteolytic stability can play an important role in enhancing the efficacy of labile growth factors such as FGF1. Studies have shown that FGF1 is rapidly degraded in culture, partly due to proteases seen in serum or expressed by cells. In Example 2, engineering of FGF1 for increased proteolytic stability is described. Screening of the FGF1 random mutagenesis library for FGF1 mutants exhibiting improved proteolytic stability on surface yeast. In this example, recombinant expression of soluble FGF1 and characterization of mutations identified by high-throughput screening to improve proteolytic stability in FGF1 are described. FGF1 and FGF2 were recombinantly expressed and purified in Escherichia coli expression system. The FGF1 BS4M1(D28N, L131R) and L131R mutants have been shown to be more proteolytically stable compared to wild-type FGF1, and the FGF1 L131R mu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods of screening for proteolytically stable growth factor variants, including, for example variants of human fibroblast growth factor 1 (FGF1). The present invention also provides for FGF1 variants comprising at least one amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1, as well as related uses.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 743,414, entitled "Engineered Fibroblast Growth Factor Variants as Receptor Antagonists," filed October 09, 2018, the contents of which are hereby incorporated by reference Incorporated into this article as a whole. [0003] field of invention [0004] The present invention relates to the field of polypeptide variants, in particular fibroblast growth factor (FGF) variants. [0005] Background of the invention [0006] Human growth factors play a key role in orchestrating many complex processes such as wound healing, tissue regeneration, angiogenesis and tumor formation 1-4 . Therefore, there is great interest in utilizing growth factors as protein therapeutics to accelerate wound healing and regeneration processes, or to inhibit cancer growth and angiogenesis in a variety of diseases and disorders 5-7 . However, although many recombinant g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18
CPCC07K14/50A61K38/00A61P35/00A61P27/00A61K38/1825A61K47/00A61K51/02C12N15/01
Inventor 朴成珍珍妮弗·科克伦
Owner THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap